FG
STLN

Formula Growth’s Starling Oncology STLN Stock Holding History

Formula Growth’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
+300,000
New +$1.26M 0.57% 68

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Formula Growth's STLN Position: Q2 2026 in Review

Formula Growth opened a new position in Starling Oncology (STLN) in Q2 2026: 300,000 shares worth $1.63M. The stake represents 0.57% of the portfolio and ranks #68 among its holdings.

120 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Formula Growth held 300,000 shares of Starling Oncology worth $1.63M as of Q2 2026.
  • Starling Oncology was a new Formula Growth position in Q2 2026.
  • Starling Oncology made up 0.57% of Formula Growth's portfolio in Q2 2026, its #68 holding.
  • 120 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Formula Growth's 13F filing for Q2 2026, filed 17 Aug 2026.